i-Pharm GxP’s Post

This mindset is key to success in the biotechnology sector. Scientific breakthroughs and innovation are built on the back of failure. Over 100 bispecific antibodies are currently in clinical development, but just 14 have been approved since 2009. If we only began development when we could guarantee success, not a single antibody would have been approved. #Failure #Mindset #Biotechnology #BusinessInnovation

Side-by-Side Economic Process Model for the Comparison and Evaluation of Magnetic Bead-Based Processes and Legacy Process for the Manufacturing of Monoclonal Antibodies This study models two alternative downstream processes based on magnetic separation with the objective of understanding the economic feasibility of these processes compared to the traditional mAb process. The key focus lies in the economic understanding of the cell harvest and capture steps in the models. Here, the models revealed that integrating cell removal and product capture in a single operation is the main factor driving the unified productivity between USP and the magnetic bead-based processes. This results in significant economic benefits, such as savings in both the cost of goods per gram of mAb and fixed costs, as well as increasing annual facility output. The predicted savings potential approaches 38% for COGs, 17% for capital investment, and 40% for annual facility output. https://lnkd.in/dZatEDQq #aspenalert #biotech #bioprocess

🎉 Nuclera Secures US$75M to Advance Protein Discovery System 🧬 Exciting news from the biotech world! Nuclera, a company specializing in next-generation protein discovery, has successfully raised $75 million in funding. This new investment will help accelerate the development and scaling of their pioneering eProtein™ platform, which aims to revolutionize how researchers and pharmaceutical companies work with proteins. Proteins are the building blocks of life, and the ability to rapidly discover and produce them will have wide-reaching applications, from drug discovery to synthetic biology. Nuclera's system is designed to bring speed and efficiency to the protein discovery process, potentially transforming research outcomes across multiple industries. This funding round demonstrates confidence in Nuclera’s vision to streamline biotech innovation and make protein research more accessible. Looking forward to seeing how this progress unfolds! 🌍🔬 https://lnkd.in/e6MwucU8 #Biotech #ProteinDiscovery #Innovation #Nuclera #FundingNews #Biotechnology #LifeSciences #DrugDiscovery #TechAdvancement #ScienceInnovation #eProtein #Research #Proteins

Discover how Constructive Bio is building beyond nature to create the next generation of biomolecules. Using synthetic genomes and non-canonical amino acids, this UK-based biotech is developing therapeutics with enhanced molecular and chemical properties. Just look at drugs like Wegovy and Ozempic — their active ingredient semaglutide incorporates a non-canonical amino acid to improve drug stability. Now imagine how this technology will expand the toolkit available not only for drug development, but across industries. With Constructive’s ability to design molecules with unprecedented specificity and fidelity, they’re unlocking the next generation of biologics — and doing so in a more sustainable and scalable way. See how they’re using Benchling to centralize their data and scale their R&D. We’re proud to support their mission! 🧬🧑🔬 https://lnkd.in/emjEFqAz #BuiltOnBenchling

Do you want to know more about the latest in oligonucleotide research? Explore our extensive library of educational videos. Discover the latest trends and breakthroughs. Learn from top researchers and experts in the field. Start learning today: https://lnkd.in/gn9pdUs3 #ots #oligotherapeutics #oligonucleotide #biotech #biotechnology #science #research #pharmaceuticals #networking #otsmember #educationalvideos #currentresearch #educationalvideos #educationalresources

BIO24 has concluded and the biotech executives are heading home. So are we, at Trailhead Biosystems. We thank all those we met, both those we planned to meet in advance but as much also those we met unexpectedly and learned from. Opportunities are everywhere - but only if we meet! BIO is an event that needs to be experienced - it is difficult to describe the intensity. The skies of future biotechnology are awaiting many new companies and cures. After BIO24 it feels as the turbulent time of the biotechnology sector is calming. That is good, as perfection takes time and continuity of focus gives results. If you think long acting Glp1R agonists came overnight, think again. Drugs, Biologics, and Cell Therapies are difficult. Very difficult. This industry takes Time. Commitment. Investment. Trailhead Biosystems #bio24 #cellandgenetherapy #trailbio #hddoe #biotechnology #t1d #hsct #futuremedicine #ipsc #biomanufacturing

Constructive Bio is pushing the boundaries of synthetic biology, and Benchling has been a key partner in this journey. Their platform helps us manage complex data and streamline workflows as we scale genome writing and engineered translation. Learn how we’re pioneering the future of biology:

One day to go……. HuidaGene Therapeutics team is meeting with partners, collaborators, and investors at #BIOEurope Fall organized by EBD Group and Biotechnology Innovation Organization to discuss our novel CRISPR nucleases for #medicines and agrisciences and our robust pipeline to tackle previously untreatable #diseases . Reach out to Xixi Zhu and set up meeting through partneringONE by Informa Connect to see how our versatile gene-editing toolbox can solve your current drug development challenges or how we can use #CRISPR #geneediting to combat #climatechange. #BioEurope2024 #BioEurope24 #business #businessdevelopment #collaboration #partnership #investment #biotechnology #science #pharmaceutical #agriculture #technology

My recent perspective on post-pandemic #biotech #leapfrogging in Trends in Biotechnology (2024). Here is the link for fellow fans of biotech stocks: https://lnkd.in/grmFZQ7A Trends in Biotechnology

🌟 Join Our Exclusive Manufacturing Roundtable Sessions (Track 3), Oligonucleotide Therapeutics Xchange, Boston. 🌟 Register for free: https://bit.ly/3wYHLnQ Are you passionate about the latest advancements in manufacturing and eager to stay ahead of the curve in the biotech industry? Don't miss out on our upcoming roundtable sessions, expertly tailored for you! 📅 Date: June 21, 2024 ⏰ Time: 08:00 - 17:40 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US ⭐ Here's the highlights: 📑 Downstream manufacturing challenges for synthetic oligonucleotides. 🗣️ Firoz Antia, Executive Director, Head of Oligonucleotide Development, Biogen 📑 Current challenges for drug substance CDMOs in the Oligonucleotide space. 🗣️ Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group 📑 Novel methodologies to manufacture Oligonucleotides. 🗣️ Mayur Patel, PhD, Director, Oligonucleotides Chemistry, Korro Bio, Inc. Our Partners 🔺 ChemGenes 🔺 PolyPeptide Group 🔺 Nitto Avecia 🔺 WuXi Biologics 🔺 Nostrum Biodiscovery 🔺 Vazyme Biotech * Agenda subject to change. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #Manufacturing #Biotech #Oligonucleotides #Networking #ProfessionalDevelopment #Pharma #Biotechnology #Chemistry #Science #Innovation #Roundtable #Roundtables #NetworkingEvent #IndustryLeaders #BusinessDevelopment #CareerGrowth #LearningOpportunity #NetworkingRoundtables #Research #Technology #Collaboration #Leadership #Expertise #Insights #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass